Needham Maintains Buy on Hims & Hers Health, Raises Price Target to $42
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $35 to $42.
Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $35 to $42.